Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

TLX vs QURE: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TLX Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 6–4 Matrix Metrics)

TLX Overall Winner 6-Pillar Tally: TLX 4 – 2 QURE Matrix Metrics: TLX 6 – 4 QURE

As of Nov 16, 2026, Telix Pharmaceuticals Limited (TLX) is the stronger overall head-to-head candidate over uniQure N.V. (QURE) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). TLX carries a Unified Composite Score of 46.4/100 (HOLD) at $8.96 (N/M Forward P/E, 6.2% operating margin), whereas QURE carries 48.9/100 (HOLD) at $22.10 (27.9x Forward P/E, -994.0% operating margin).

  • Composite vs. Pillar Nuance: While QURE currently prints a higher short-term Unified Composite Score (48.9/100 HOLD vs. TLX 46.4/100 HOLD), TLX captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (6.2% vs. -994.0% operating margin) and revenue trajectory (+22.3% vs. +40.4% YoY).
  • Technical & Structure Timing Caution: TLX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.0); meanwhile QURE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About TLX vs QURE
TLX NASDAQ Head-to-Head Winner
Telix Pharmaceuticals Limited American Depositary Shares
Pharmaceutical Preparations
$8.96
-2.98% 1D
Market Cap $3.2B
TTM Revenue $891M
Forward P/E N/M
Beta / 30D Vol 0.84β · 62% Vol
Unified Composite Score
46.4 / 100 HOLD
Tech 64.0 Fund 62.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.7%), weak momentum, RSI 39
RSI-14: 39.0 · SMA20: $9.46 · SMA50: $10.61
QURE NASDAQ
uniQure N.V.
Pharmaceutical Preparations
$22.10
-7.18% 1D
Market Cap $1.7B
TTM Revenue $20M
Forward P/E 27.9x
Beta / 30D Vol 0.81β · 81% Vol
Unified Composite Score
48.9 / 100 HOLD
Tech 42.0 Fund 55.0 Flow 69.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -25.1%), weak momentum, RSI 40
RSI-14: 39.9 · SMA20: $23.25 · SMA50: $29.05

6-Pillar Scorecard Institutional Category Breakdown (TLX 4 – 2 QURE)

Columns: Metric · TLX · QURE
1. Valuation Multiples QURE
Forward P/E N/M 27.9x
Trailing P/E 93.6x 27.9x
PEG Ratio N/M N/M
EV / Revenue 3.6x 83.9x
2. Growth & Scale TLX
Revenue Growth (YoY) +22.3% +40.4%
Earnings Growth (YoY) +0.0% -18.2%
TTM Revenue (USD) $891M $20M
Market Cap $3.2B $1.7B
3. Profitability & Quality TLX
Gross Margin 47.6% N/A
Operating Margin 6.2% -994.0%
Net Profit Margin 3.8% 0.0%
Return on Equity (ROE) 7.4% -89.0%
4. Balance Sheet & Cash Flow TLX
Cash Generation (TTM) $70M EBITDA -$193M
Cash Flow Margin 7.8% EBITDA Mgn N/A
Net Cash / Leverage $1.44 Book/Sh · 7.4% ROE $36M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning QURE
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 56.2% (<1st %ile)
Put/Call OI Skew Thin ADR Chain 0.14x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat TLX
OpEx & R&D Intensity 41.4% of Rev ($369M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: TLX (6) vs QURE (4)
Institutional Metric TLX QURE Criterion Row Edge
Market Capitalization
Scale
$3.2B $1.7B Larger Scale TLX
Trailing P/E Ratio
Valuation
93.6x 27.9x Lower Multiple QURE
Forward P/E Ratio
Valuation
N/M 27.9x Lower Multiple QURE
Revenue Growth (YoY)
Growth
+22.3% +40.4% Higher Growth QURE
Operating Margin (TTM)
Profitability
6.2% -994.0% Higher Margin TLX
Net Profit Margin
Profitability
3.8% 0.0% Higher Margin TLX
Return on Equity (ROE)
Capital Efficiency
7.4% -89.0% Higher ROE TLX
52-Week Range Position
Momentum
39% ($6–$13) 31% ($9–$52) Stronger Trend TLX
Beta / 30D Volatility
Risk Regime
0.84β · 62% Vol 0.81β · 81% Vol Lower Realized Risk TLX
Unified Institutional Score
Composite Signal
46.4 / 100 (HOLD) 48.9 / 100 (HOLD) Higher Composite QURE
Trailing 12M Revenue (USD)
Operating Scale
$891M $20M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
47.6% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.6x EV/Rev N/M PEG · 83.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$70M EBITDA ($1.44 Book/Sh · 7.4% ROE) -$193M ($36M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon QURE +17.7 pp
TLX: -16.23% · QURE: +1.47%
3M Horizon TLX +28.74 pp
TLX: -24.62% · QURE: -53.36%
6M Horizon QURE +1.54 pp
TLX: -12.89% · QURE: -11.35%
1Y Horizon TLX +21.32 pp
TLX: -5.84% · QURE: -27.16%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TLX vs QURE. Trailing 12-month operating profitability (TLX 6.2% vs QURE -994.0%) and valuation multiples (TLX N/M vs QURE 27.9x Forward P/E) are benchmarked directly in Pillar 4 below.

TLX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$891M
Gross Margin47.6%
Op. Margin6.2%
ROE / Fwd P/E7.4% · N/M
QURE ADR TTM Benchmark FX-Normalized USD
TTM Revenue$20M
Gross MarginN/A
Op. Margin-994.0%
ROE / Fwd P/E-89.0% · 27.9x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
TLX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TLX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
QURE BREAKDOWN
102d in phase · OBV NEUTRAL
Current IV 56.2%
IV Percentile <1st %ile
Put/Call OI Skew 0.14x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact QURE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
TLX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.2B market capitalization and 6.2% operating margin.
OpEx & R&D Reinvestment 41.4% of Rev ($369M)
90D Engineering Disclosures 0 Published
QURE Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.7B market capitalization and -994.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ TLX vs QURE Key Questions & Quantitative Answers

As of Nov 16, 2026, Telix Pharmaceuticals Limited (TLX) is the stronger overall head-to-head candidate over uniQure N.V. (QURE) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). TLX carries a Unified Composite Score of 46.4/100 (HOLD) at $8.96 (N/M Forward P/E, 6.2% operating margin), whereas QURE carries 48.9/100 (HOLD) at $22.10 (27.9x Forward P/E, -994.0% operating margin). Composite vs. Pillar Nuance: While QURE currently prints a higher short-term Unified Composite Score (48.9/100 HOLD vs. TLX 46.4/100 HOLD), TLX captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (6.2% vs. -994.0% operating margin) and revenue trajectory (+22.3% vs. +40.4% YoY). Technical & Structure Timing Caution: TLX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.0); meanwhile QURE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

TLX leads the Growth & Scale pillar: TLX posts +22.3% YoY revenue growth and +0.0% YoY earnings growth on $891M TTM revenue (47.6% gross margin, 6.2% operating margin), compared with QURE at +40.4% YoY revenue growth and -18.2% YoY earnings growth on $20M TTM revenue (N/A gross margin, -994.0% operating margin). On trailing 12-month operating scale, TLX generates $891M in USD-normalized revenue versus $20M for QURE. In operating R&D and SG&A reinvestment, TLX deploys 41.4% of Rev ($369M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for QURE.

QURE screens cheaper on headline valuation multiples. TLX trades at N/M Forward P/E, 93.6x Trailing P/E, N/M PEG, and 3.6x EV/Revenue (7.8% EBITDA margin), whereas QURE trades at 27.9x Forward P/E, 27.9x Trailing P/E, N/M PEG, and 83.9x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TLX (7.4% ROE) versus QURE (-89.0% ROE) capital efficiency.

In options market volatility and institutional positioning, TLX carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.84β · 62% Vol realized risk). By comparison, QURE carries 56.2% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.14x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.81β · 81% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.